AZD 9898

Drug Profile

AZD 9898

Alternative Names: AZD9898

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orexo
  • Developer AstraZeneca
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action Leukotriene-C4 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma

Most Recent Events

  • 13 Sep 2017 Pharmacodynamic results from preclinical studies in Asthma presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
  • 10 May 2017 Phase-I clinical trials in Asthma in United Kingdom (PO) (NCT03140072)
  • 25 Jan 2013 Preclinical trials in Respiration disorders in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top